CompletedPhase 3NCT02065882
Pharmacokinetic, Efficacy and Safety of BT524 in Patients With Congenital Fibrinogen Deficiency
Studying Congenital fibrinogen deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Biotest
- Principal Investigator
- Claudia Djambas Khayat, MDHôtel Dieu de France, Dept. of Pediatrics
- Intervention
- BT524 (Part I)(drug)
- Enrollment
- 67 enrolled
- Eligibility
- 75 years · All sexes
- Timeline
- 2013 – 2020
Study locations (6)
- Site 15, Sofia, Bulgaria
- Site 11, Cairo, Egypt
- Site 16, Frankfurt, Germany
- Site 01, Beirut, Lebanon
- Site 14, Sousse, Tunisia
- Site12, Tunis, Tunisia
Collaborators
ICON plc · Phoenix Clinical Research · Accovion GmbH
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02065882 on ClinicalTrials.govOther trials for Congenital fibrinogen deficiency
Additional recruiting or active studies for the same condition.